An Open Label Study To Evaluate The Safety And Efficacy Of First Ribavirin-Free Sofosbuvir And Simeprevir Therapy In Hepatitis C Genotype 1 Patients With Severe Renal Impairment (GFR <30 mL/min OR DIALYSIS).

Trial Profile

An Open Label Study To Evaluate The Safety And Efficacy Of First Ribavirin-Free Sofosbuvir And Simeprevir Therapy In Hepatitis C Genotype 1 Patients With Severe Renal Impairment (GFR <30 mL/min OR DIALYSIS).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2015

At a glance

  • Drugs Simeprevir (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top